Implanted intrathecal drug delivery systems may be associated with improved survival in patients with cancer

Mitchell, A., Somerville, L., Williams, N., McGhie, J., McConnachie, A. , McGinn, G. and Lee, J. (2024) Implanted intrathecal drug delivery systems may be associated with improved survival in patients with cancer. British Journal of Pain, 18(2), pp. 110-119. (doi: 10.1177/20494637231202089) (PMID:38545502)

[img] Text
313007.pdf - Accepted Version

604kB

Abstract

Background: Intrathecal Drug Delivery Systems (IDDS) are underused in the management of cancer-related pain despite evidence of both efficacy and survival benefit. There is currently limited evidence to indicate which patients might benefit most from IDDS. Aim: The aim of the study was to describe the baseline characteristics and survival outcomes of patients who accepted IDDS, patients who declined IDDS and patients who wished to go ahead with IDDS but whose condition deteriorated before they could do so. Design/participants The survival data for 75 consecutive patients who had been offered intrathecal drug delivery were examined as part of a retrospective cohort study. Survival data was compared between three groups: those who accepted intrathecal drug delivery and went on to receive it (n = 41), those who accepted it but whose condition deteriorated before it commenced (n = 17) and those who declined this treatment modality (n = 17). Results: Patients who received IDDS survived significantly longer after assessment compared to those who declined IDDS (hazard ratio (HR) for the IDDS group relative to the declined group 0.29 (95% CI 0.16 to 0.53), and 0.23 (95% CI 0.12 to 0.44) after adjustment for gender and baseline functional status. In patients who accepted IDDS but who were unable to commence treatment, survival after assessment was not significantly different from those who declined the IDDS (HR for the deteriorated group relative to the declined group 1.28 (95% CI 0.65 to 2.53), and 0.80 (95% CI 0.65 to 2.53) after adjustment for gender and baseline functional status). Conclusion: In this retrospective analysis, an improvement in survival may be associated with patients who accept ongoing pain management with an implanted intrathecal drug delivery system compared to those patients who either declined intrathecal drug delivery or deteriorated before it could be commenced.

Item Type:Articles
Additional Information:This work was supported by the Statistical analysis was funded by NHS GGC Endowment Fund.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McConnachie, Professor Alex and Lee, Miss Jiyoung
Authors: Mitchell, A., Somerville, L., Williams, N., McGhie, J., McConnachie, A., McGinn, G., and Lee, J.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
Journal Name:British Journal of Pain
Publisher:SAGE Publications
ISSN:2049-4637
ISSN (Online):2049-4645
Published Online:16 October 2023
Copyright Holders:Copyright © 2023 The Author(s)
First Published:First published in British Journal of Pain 18(2): 110-119
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record